ES2193069T3 - Formulacion farmaceutica en aerosol. - Google Patents

Formulacion farmaceutica en aerosol.

Info

Publication number
ES2193069T3
ES2193069T3 ES00925450T ES00925450T ES2193069T3 ES 2193069 T3 ES2193069 T3 ES 2193069T3 ES 00925450 T ES00925450 T ES 00925450T ES 00925450 T ES00925450 T ES 00925450T ES 2193069 T3 ES2193069 T3 ES 2193069T3
Authority
ES
Spain
Prior art keywords
formulations
aerosol
pharmaceutical formulation
relates
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00925450T
Other languages
English (en)
Inventor
Cecile Isabelle Bonvoisin
Christophe Laroche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921289.6A external-priority patent/GB9921289D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2193069T3 publication Critical patent/ES2193069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una formulación farmacéutica en aerosol que comprende: (A) xinafoato de salmeterol en forma de partículas revestidas mediante secado por pulverización con al menos un tensioactivo en ausencia de cualquier otro excipiente de revestimiento, en suspensión en (B) un gas licuado como propelente que es 1, 1, 1, 2, 3, 3, 3-heptafluoro-n-propano o 1, 1, 1, 2-tetrafluoroetano y mezclas de los mismos.
ES00925450T 1999-04-14 2000-04-13 Formulacion farmaceutica en aerosol. Expired - Lifetime ES2193069T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BH12699 1999-04-14
GBGB9921289.6A GB9921289D0 (en) 1999-09-10 1999-09-10 Pharmaceutical aerosol formulation

Publications (1)

Publication Number Publication Date
ES2193069T3 true ES2193069T3 (es) 2003-11-01

Family

ID=25663377

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00925450T Expired - Lifetime ES2193069T3 (es) 1999-04-14 2000-04-13 Formulacion farmaceutica en aerosol.

Country Status (10)

Country Link
US (1) US7090831B1 (es)
EP (1) EP1169019B1 (es)
JP (1) JP2002541183A (es)
AT (1) ATE233084T1 (es)
AU (1) AU4417500A (es)
DE (1) DE60001492T2 (es)
DK (1) DK1169019T3 (es)
ES (1) ES2193069T3 (es)
PT (1) PT1169019E (es)
WO (1) WO2000061108A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064613A1 (en) * 2006-09-11 2008-03-13 M-I Llc Dispersant coated weighting agents
EP2283818B1 (en) * 2000-11-30 2017-08-02 Vectura Limited Method of making particles for use in a pharmaceutical composition
EP2168571B1 (en) * 2000-11-30 2018-08-22 Vectura Limited Particles for use in a Pharmaceutical Composition
AU2002222304B2 (en) * 2000-12-22 2004-03-18 Glaxo Group Limited Metered dose inhaler for salmeterol xinafoate
MXPA04002401A (es) * 2001-09-14 2004-05-31 Boehringer Ingelheim Pharma Nuevos medicamentos para inhalacion.
AU2003259910A1 (en) * 2002-08-14 2004-03-03 E.I. Du Pont De Nemours And Company Process for coating a pharmaceutical particle
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
MXPA05012467A (es) * 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
GB0321607D0 (en) † 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005051511A1 (ja) * 2003-11-28 2005-06-09 Mitsubishi Chemical Corporation 有機化合物微粒子の製造方法
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP2213165A1 (en) * 2007-11-27 2010-08-04 Erc Technology Inc. Novel compositions containing ozonized surfactant
EP2393488B1 (en) 2009-02-06 2019-06-19 University Of Southern California Therapeutic compositions comprising monoterpenes
MX337126B (es) 2009-05-29 2016-02-12 Pearl Therapeutics Inc Administracion respiratoria de agentes activos.
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
DK2453894T3 (en) 2009-07-15 2016-01-25 Theravance Biopharma R&D Ip Llc Crystalline free base of a biphenyl compound
EP2542082B8 (en) 2010-03-03 2020-06-17 Neonc Technologies Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-perillyl alcohol
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
DK3685835T3 (da) 2010-08-27 2025-07-21 Univ Southern California Farmaceutiske sammensætninger, der omfatter derivater af perillylalkohol
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
RU2629085C2 (ru) 2011-10-11 2017-08-24 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Кристаллические микрочастицы бета-агониста, покрытые жирной кислотой
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
EP2968313B1 (en) 2013-03-15 2018-01-31 Verona Pharma PLC Drug combination
DE102013021718B4 (de) * 2013-12-20 2017-03-02 Gerresheimer Regensburg Gmbh Kapsel zur Verwendung als Reservoir für eine pharmazeutische, vorzugsweise pulverförmige Zubereitung in einem Inhalator sowie Inhalator dafür
DK3142701T3 (en) 2014-05-12 2018-08-13 Verona Pharma Plc New treatment
JP6674957B2 (ja) 2015-02-12 2020-04-01 ネオンク テクノロジーズ インク． ペリリルアルコール誘導体を含む医薬組成物
EP3547836B1 (en) 2016-11-30 2024-08-21 University of Southern California A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
CN111936125B (zh) 2018-02-08 2025-03-04 南加州大学 穿透血脑屏障的方法
WO2021216710A1 (en) 2020-04-24 2021-10-28 The Medical College Of Wisconsin, Inc. Use of salmeterol as an anti-coronaviral agent

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1535531A (en) * 1976-10-15 1978-12-13 Warmer & Co Ltd W Pharmaceutical compositions
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
EP0257915B1 (en) 1986-08-11 1993-03-10 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
JPH05507090A (ja) 1990-05-08 1993-10-14 リポサーム　テクノロジー　インコーポレイテッド 直接噴霧乾燥された薬剤／脂質粉末組成物
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
GB9026005D0 (en) 1990-11-29 1991-01-16 Glaxo Group Ltd Drug material suitable for micronisation
DK0616524T3 (da) 1991-12-12 1999-06-21 Glaxo Group Ltd Lægemidler
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ATE137666T1 (de) 1991-12-31 1996-05-15 Hoechst Ag Medizinische aerosolformulierung
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
EP0655237A1 (de) 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
JPH08151322A (ja) * 1994-09-30 1996-06-11 Takeda Chem Ind Ltd 経口徐放剤
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
ID27887A (id) 1998-04-18 2001-05-03 Glaxo Group Ltd Formulasi aerosol farmasi
GB9828721D0 (en) 1998-12-24 1999-02-17 Glaxo Group Ltd Novel apparatus and process

Also Published As

Publication number Publication date
US7090831B1 (en) 2006-08-15
DK1169019T3 (da) 2003-06-02
ATE233084T1 (de) 2003-03-15
EP1169019A1 (en) 2002-01-09
DE60001492T2 (de) 2003-12-18
JP2002541183A (ja) 2002-12-03
EP1169019B1 (en) 2003-02-26
WO2000061108A1 (en) 2000-10-19
PT1169019E (pt) 2003-07-31
AU4417500A (en) 2000-11-14
DE60001492D1 (de) 2003-04-03

Similar Documents

Publication Publication Date Title
DK1169019T3 (da) Farmaceutisk aerosolformulering
AP2000001961A0 (en) Pharmaceutical aerosol formulation.
DE60123793D1 (de) Neue aerosolformulierungen ein polares fluoriniertes molekül enthaltend
ES2178817T3 (es) Formulaciones medicinales de aerosol.
IT1255040B (it) Forma di ciclosporina adatta alla somministrazione per via polmonare eprocedimento di preparazione.
CA2338753A1 (en) Medicinal aerosol formulations
NO20025593D0 (no) Aerosolbeholder for formuleringer av salmeterol-xinafoat
DE60321774D1 (de) Aerosol-formulierungen von formoterol und mometason
AU2206801A (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
HUP0002691A2 (hu) Ciklezonid tartalmú gyógyászati aeroszol termékek
WO2002085338A3 (en) Ipratropium formulation for pulmonary inhalation
DE69102161D1 (de) Gemische von Dimethyläther und 1,1,1,2-Tetrafluoräthan und deren Verwendungen.
WO2002076176A3 (en) Mixtures containing 1,1,1,3,3-pentafluoropropane and 1,1,1,3,3-pentafluorobutane
WO1999024016A8 (en) Emulsions for aerosolization and drug delivery
AU1534501A (en) Pharmaceutical formulations of salmeterol
TH29519B (th) สูตรผสมทางเภสัชศาสตร์ที่เสถียรชนิดใหม่สำหรับการผลิตละอองลอยที่ไม่มีแก๊สผลักดัน